Last $19.17 USD
Change Today +0.005 / 0.03%
Volume 1.9M
EXAS On Other Exchanges
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

exact sciences corp (EXAS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/14 - $23.20
52 Week Low
10/9/13 - $9.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EXACT SCIENCES CORP (EXAS)

exact sciences corp (EXAS) Related Businessweek News

No Related Businessweek News Found

exact sciences corp (EXAS) Details

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company’s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

102 Employees
Last Reported Date: 02/28/14
Founded in 1995

exact sciences corp (EXAS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $738.5K
Principal Financial Officer and Senior Vice P...
Total Annual Compensation: $84.6K
Chief Operating Officer, Senior Vice Presiden...
Total Annual Compensation: $508.3K
Chief Science Officer and Senior Vice Preside...
Total Annual Compensation: $474.3K
Compensation as of Fiscal Year 2013.

exact sciences corp (EXAS) Key Developments

Exact Sciences Corporation Announces Mayo Clinic as First Healthcare System to Offer Cologuard(R)

Exact Sciences Corporation announced that Mayo Clinic will be the first health system to offer Cologuard(R), the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer. Cologuard will be available to patients through their primary care physicians at Mayo Clinic. Available by prescription only, Cologuard offers people 50 years and older who are at average risk for colorectal cancer an easy to use screening test which they can do in the privacy of their own home. It is the first noninvasive screening test for colorectal cancer that analyzes both stool-based DNA and blood biomarkers to detect cancer and precancer. Cologuard is designed to detect DNA alternations and blood released from cancer and precancerous colon lesions. The test requires a physican order.

MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay

MDxHealth SA announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard(R) stool-DNA-based, non-invasive colorectal cancer screening test. The test incorporates one of MDxHealth's epigenetic biomarkers, which was licensed to Exact Sciences in July 2010. Upon product launch, anticipated before the end of 2014, MDxHealth expects to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement. The FDA approval of Cologuard marks the first stool-based colorectal screening test to earn this designation. Cologuard detects specific changes in a patient's DNA that appear in the stool, which could indicate the presence of colorectal cancer or pre-cancerous polyps. The test also identifies the presence of blood in the stool, another indicator of possible colorectal cancer. Patients with positive test results are advised to undergo a diagnostic colonoscopy. The Centers for Medicare & Medicaid Services (CMS) has issued a preliminary decision on covering the cost of the test, proposing a three-year testing interval for people ages 50 to 85 with no cancer symptoms. The proposal is subject to a 30-day comment period and final action is expected in November.

Exact Sciences Corp. Announces Appointment to its Board

Exact Sciences Corp. announced that James E. Doyle and Maneesh K. Arora were elected to company's board of directors at its annual meeting of stockholders. Lionel N. Sterling has served as a director of Exact since 2010 and was reelected to the board. Gov. James E. Doyle served two terms as governor of Wisconsin. Maneesh K. Arora has served as Exact's chief operating officer since February 2012 and as a senior vice president since April 2009, when he joined the company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXAS:US $19.17 USD +0.005

EXAS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $14.05 USD -0.04
Curis Inc $1.52 USD -0.04
Delcath Systems Inc $2.18 USD -0.11
MELA Sciences Inc $1.86 USD -0.03
Navidea Biopharmaceuticals Inc $1.33 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation EXAS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 664.4x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 571.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXACT SCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at